Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, UroGen Pharma's enterprise value is $2,211.5 Mil.
UroGen Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-79.3 Mil. Therefore, UroGen Pharma's EV-to-EBITDA for today is -27.90.
The historical rank and industry rank for UroGen Pharma's EV-to-EBITDA or its related term are showing as below:
LTS:0XOD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -156.71 Med: -4.22 Max: 191.49
Current: -27.9
During the past 11 years, the highest EV-to-EBITDA of UroGen Pharma was 191.49. The lowest was -156.71. And the median was -4.22.
LTS:0XOD's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 13.91
vs LTS:0XOD: -27.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
UroGen Pharma's PE Ratio (TTM) for today is calculated as:
UroGen Pharma's share price for today is $43.80.
UroGen Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.980.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for UroGen Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0XOD vs PVLA, KLRA, VCEL: EV-to-EBITDA Comparison
For the Biotechnology subindustry, UroGen Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's EV-to-EBITDA falls into.
UroGen Pharma's current Enterprise Value is $2,211.5 Mil.
UroGen Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-79.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (LTS:0XOD) has a EV-to-EBITDA of -27.90 as of Sep. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on UroGen Pharma. According to the industry distribution chart, UroGen Pharma ranks #999999 out of 402 companies in the Biotechnology industry.
Is UroGen Pharma's EV-to-EBITDA too high?
UroGen Pharma's current EV-to-EBITDA is -27.90. Based on the distribution chart, UroGen Pharma ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UroGen Pharma has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's EV-to-EBITDA compare to PVLA and KLRA?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #999999 out of 402 companies for EV-to-EBITDA. This places UroGen Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 13.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.91, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on UroGen Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 13.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current EV-to-EBITDA is -27.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $27.37, compared to a current price of $43.80 — trading 60% above its estimated fair value. The current EV-to-EBITDA is -27.90. UroGen Pharma's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current EV-to-EBITDA is -27.90 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of $43.80 is trading 60% above its estimated GF Value™ of $27.37.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0XOD:
EV-to-EBITDA: -27.90
GF Value™: $27.37 vs. price of $43.80 (60% above fair value)
No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
53GF Score
Get the complete analysis for LTS:0XOD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0XOD has been successfully added to your 
